ADC Therapeutics S.A. (ADCT) Stock Chart - Revenue & Earnings | Quarter Chart

📊 Income Statement

Revenue by Product

Revenue by Geography

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income
08M15M22M30M38M45M52M60MQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Margin (%)

Gross MarginOperating MarginNet Income Margin
0255075100125150175200Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Operating Expenses

Research And Development ExpensesSelling And Marketing ExpensesGeneral And Administrative ExpensesOther Expenses
010M20M30M40M50M60M70M80MQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025

EBITDA

EBITDA
-50M-44M-37M-31M-25M-19M-12M-6M1Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

EPS

Revenue Variation (%)

Revenue Variation
-30-20-1001020304050Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Income Variation (%)

Gross Profit VariationOperating Income Variation
0918263544526170Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Revenue YoY Variation (%)

Revenue YoY Variation
-20-12-521018253240Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Income YoY Variation (%)

Gross Profit YoY VariationOperating Income YoY Variation
01020304050607080Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Price-to-Earning Ratio

P/E Ratio
-4-3-3-2-2-1-001Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Income Breakdown

Operating IncomeInterest IncomeTotal Other Income Expenses NetNet Income
0625K1M2M2M3M4M4M5MQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Per Share Metrics

Revenue Per ShareNet Income Per ShareOperating Cash Flow Per Share
000001111Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Expense Ratios

Research And Ddevelopement To RevenueCapex To RevenueStock Based Compensation To Revenue
001122233Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
💰 Cash Flow Statement

Operating Cash Flow

Free Cash Flow

Cash At End Of Period
050M100M150M200M250M300M350M400MQ3 2024Q4 2024Q1 2025Q2 2025

Cash Flow to Debt Ratio

Net Cash Provided By Operating ActivitiesNet Cash Used Provided By Financing Activities
025M50M75M100M125M150M175M200MQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025
🏦 Balance Sheet
📈 Key Metrics